glp-1 dialysis receptor agonists in patients with chronic kidney disease and either overweight or obesity Potential Mechanisms for Pro-Vascular Benefit

Start the assessment: Step 2: Provider Review and Consult A licensed provider reviews your intake and connects with you through Ivy Rxs secure portal

Food and Drug Administration (FDA) issued more than 50 warning letters to compounding pharmacies and manufacturers marketing compounded versions of GLP-1 class drugs, such as semaglutide and tirzepatide

That's when it starts getting dangerous

How does a substance or method get included on the WADA Prohibited List

Emerging research suggests a strong connection between gut health and skin conditions like eczema

Understanding how to optimize fiber consumption during GLP-1 treatment helps patients achieve better therapeutic outcomes and improved digestive comfort throughout their medication journey